Vimovo

Biggest single investment in Grünenthal’s history that will significantly strengthen the company’s leading position in pain management Gastroprotective therapies to address a high unmet medical need[1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and … Skaityti toliau